One is that your dose may not be high enough, Cody Stanford said. A recent study involving about 3,390 people taking semaglutide or liraglutide, another GLP-1 for obesity, found that participants who ...

Denmark-based Novo Nordisk teased some new details about a potential Ozempic successor during a call with investors on Tuesday. Sales of the company’s current blockbuster weight loss drug, Wegovy, ...

There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

The medications affected by this update include liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...

The combination of these factors will support growth in the biosimilar segment. For the generics segment, Liraglutide will be ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

The drugs affected by the new warning include: Semaglutide, with brand names Ozempic, Rybelsus, and Wegovy Liraglutide, which ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

The updated AAP clinical guidelines on obesity treatment recommend offering the full spectrum of care upon initial obesity ...